Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medpace (MEDP) closed the most recent trading day at $395.95, moving +0.52% from the previous trading session.

Medpace (MEDP) Advances But Underperforms Market: Key Facts

AppLovin Corp

Datadog

monday.com

Wingstop

Wall Street's popular adages are not matching this year. April is historically known for being favorable to investors. But this year, April ended on a disappointing note. For May, the popular adage is "Sell and Go Away." However, last month turned out highly successful for U.S. stock markets.

5 Growth Stocks to Buy for Steady Returns in June

Goldman Sachs

Reinsurance Group of America

Texas Roadhouse

We have selected five services-oriented stocks that have strong potential for the rest of 2024. These stocks are: MEDP, TXRH, WING, GS, RGA.

U.S. Services PMI Returns to Expansion Path in May: 5 Picks

Coinbase

Tractor Supply

Five Nasdaq listed non-tech stocks that have provided more than 40% returns year to date and have more potential for growth. These are: COIN, MEDP, WING, TXRH, TSCO.

Top 5 Non-Tech Winners YTD With More Potential for Growth

Medpace Holdings is a US-based clinical research organization that is well-positioned to benefit from increased demand due to geopolitical risks affecting Chinese firms. Medpace stands out among its peers due to its growth orientation, competitive margins, and focus on next-generation therapies. While Medpace lacks diversification compared to WuXi Biologics, a pair trade strategy can help reduce risk and take advantage of the opportunities in the healthcare market.

Medpace: Clear Winner If China Blockade Succeeds

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy Medpace (MEDP) Now

Comfort Systems USA

HCI Group

Stocks like Wingstop (WING), Medpace (MEDP), Comfort Systems USA (FIX) and HCI Group (HCI) have been selected as the momentum picks for the day using the Driehaus strategy.

4 Best Momentum Stocks Worth a Buy Using Driehaus Strategy

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

American Axle & Manufacturing Hlds

Diebold Nixdorf Inc

Euronet Worldwide

Omnicom Group

Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Medpace (MEDP), American Axle & Manufacturing (AXL), Diebold Nixdorf (DBD), Euronet (EEFT) and Omnicom (OMC).

5 Stocks With Upgraded Broker Ratings Worth Investing in Now

Here is how Medpace (MEDP) and Tenet Healthcare (THC) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Medpace (MEDP) This Year?

Medpace (MEDP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Medpace Holdings, Inc. (MEDP) Is a Trending Stock: Facts to Know Before Betting on It

Netflix

UiPath

Skechers U.S.A.

We have narrowed our search to five growth stocks that have solid upside left for 2024. These stocks are NFLX, WING, PATH, SKX and MEDP.

5 Growth Stocks to Buy for Steady Returns in May

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Brokers Suggest Investing in Medpace (MEDP): Read This Before Placing a Bet

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"

Doximity

Elevance Health Inc

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, MEDP and DOCS are set to gain the most.

3 Medical Services Industry Stocks to Buy as Nursing Market Booms

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q1 2024 Earnings Call Transcript April 23, 2024 9:00 AM ET Company Participants Lauren Morris - Director of IR Jesse Geiger - President Kevin Brady - CFO August Troendle - CEO Conference Call Participants Max Smock - William Blair Eric Coldwell - Baird Jack Wallace - Guggenheim Partners Dan Leonard - UBS Justin Bowers - Deutsche Bank David Windley - Jefferies Operator Good day, ladies and gentlemen, and welcome to Medpace First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Medpace Holdings, Inc. (MEDP) Q1 2024 Earnings Call Transcript

Medpace (MEDP) came out with quarterly earnings of $3.20 per share, beating the Zacks Consensus Estimate of $2.45 per share. This compares to earnings of $2.27 per share a year ago.

Medpace (MEDP) Beats Q1 Earnings Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Revenue for the three months ended March 31, 2024 increased 17.7% to $511.0 million, compared to $434.1 million for the comparable prior-year period. On a constant currency basis, revenue for the first quarter of 2024 increased 17.6% compared to the first quarter of 2023. Backlog as of March 31, 2024 inc.

Medpace Holdings, Inc. Reports First Quarter 2024 Results

Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medpace (MEDP) Earnings Expected to Grow: Should You Buy?

Medpace (MEDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Medpace (MEDP) Beat Estimates Again in Its Next Earnings Report?

Uber

Axon Enterprise

M/I Homes

On Holding AG

Uber, Axon and one more stock with the highest-possible rating from IBD lead this weekend's watch list.

Uber Leads Five Stocks Near Buy Points

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 1.

Medpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024

Centrus Energy

NVIDIA

Trip.com

Trip.com Group Limited (TCOM), Medpace (MEDP), Centrus Energy (LEU) and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.

4 Best Profitable Stocks to Invest in Using Net Income Ratio

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why

Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

News for Medpace Holdings Stock (MEDP)